Orexigen(R) Therapeutics Announces Third Quarter 2008 Financi...(X-004 in reducing the symptoms ofobsessi...)

-- In addition, the USPTO issued U.S. Patent No. 7,425,571 providing broad coverage of the use of zonisamide either alone or in combination with other drugs for the treatment of obesity through 2023. The USPTO has also issued U.S. Patent No. 7,429,580 which broadly covers zonisamide in combination with various marketed atypical antipsychotics through 2025. Orexigen has licensed both patents on an exclusive basis from Duke University.

The Company also made a number of important presentations of data at the recent Annual Scientific Meeting of the Obesity Society. These included the following:

-- Presented data related to the impact on tolerability of naltrexone in an SR form, as compared to an earlier immediate release (IR) form. In two Phase 1 trials, Contrave utilizing the SR formulation of naltrexone successfully achieved key objectives (lowered naltrexone Cmax, increased Tmax, comparable AUC). Additionally, preliminary analysis of blinded data from nearly 4,000 patients participating in a series of four ongoing Phase 3 trials supports that the naltrexone SR formulation may be associated with tolerability advantages.

-- Summarized the impact of Contrave in the NB-201 Phase 2b trial on various markers of metabolic and cardiovascular risk. This review demonstrated that Contrave made a positive impact on HDL cholesterol, insulin and fasting glucose, as well as waist circumference. In addition, among Contrave patients who completed 24 weeks of treatment, the proportion of subjects with metabolic syndrome decreased from 31% to 15%. More than 47 million Americans have metabolic syndrome, a condition associated with increased risk of diabetes and cardiovascular disease.

-- Presented in oral and poster presentations data from the Phase 2b trial of Empatic, ZB-201. In this trial, Empatic demonstrated up to 15% r
'/>"/>